boehringer ingelheim glp-1 Obesity Innovation Is Entering Its Next Strategic Phase Ingelheim's advancement of BI 3034701, a long-acting, first-in-class triple-agonist peptide, into mid-stage development is a signal… Boehringer kickstarts two Phase III
Pay in 4 interest-free payments of $5.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20



























